Clinical assessment and management of spasticity: A review

Acta Neurologica Scandinavica

Volumn 122, Issue SUPPL. 190, 2010, Pages 62-66

  Rekand, T ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Baclofen; Botulinum toxin; Disability; Intrathecal Baclofen; Spasticity score

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; DANTROLENE; DIAZEPAM; GABAPENTIN; SPASMOLYTIC AGENT; TIZANIDINE;

CEREBRAL PALSY; CLINICAL ASSESSMENT; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE; HALLUCINATION; HUMAN; MUSCLE WEAKNESS; NEUROSURGERY; ORTHOPEDIC SURGERY; PASSIVE MOVEMENT; PHYSIOTHERAPY; QT PROLONGATION; RESPIRATORY TRACT DISEASE; REVIEW; SCORING SYSTEM; SEDATION; SIDE EFFECT; SPASTICITY; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 77953200017     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01378.x     Document Type: Review

References (47)

1. Lance WW. The control of muscle tone, reflexes and movement: Robert Wartenberg lecture. Neurology 1980;30 : 1303-1313.
2. Young RR. Spasticity: a review. Neurology 1994;44 : 512-520.
3. Gracies J-M. Pathophysiology of spastic paresis I: paresis and soft tissue changes. Muscle Nerve 2005;31 : 535-551.
4. Gracies J-M. Pathophysiology of spastic paresis II: emergence of muscle overactivity. Muscle Nerve 2005;31 : 552-571.
5. Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm 2008;115 : 607-616.
6. Ashworth B. Preliminary trial of carisopodol in multiple sclerosis. Practitioner 1964;67 : 540-542.
7. Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67 : 206-207.
8. Ghotbi N, Ansari NN, Naghdi S, Hasson S, Jamshidpour B, Amiri S. Inter-rater reliability of the modified Ashworth Scale in assessing lower limb muscle spasticity. Brain Inj 2009;23 : 815-819.
9. Tardieu G, Shentoub S, Delarue R. A la recherché d'une technique de mesure de la spasticité. Rev Neurol 1954;91 : 143-144.
10. Fosang AL, Galea MP, McCoy AT, Rediggough DS, Story I. Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol 2003;45 : 664-670.
11. Mehrholz J, Wagner K, Meiner D et al. Reliability of the modified Tardieu scale and the modified Ashworth scale in adult patients with severe brain injury: a comparison study. Clin Rehabil 2005;19 : 751-759.
12. Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;32 : 1517-1521. (Pubitemid 19145803)
13. Priebe MM, Sherwood AM, Thornby JI, Kharas NF, Markowski J. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 1996;77 : 713-716.
14. Wartenberg R. Pendulousness of the legs as a diagnostic test. Neurology 1951;1 : 18-24.
15. Biering-Sørensen F, Nielsen JB, Klinge K. Spasticity - assessment: a review. Spinal Cord 2006;44 : 708-722.
16. Malhotra S, Pandyan AS, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil 2009;23 : 651-658.
17. Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010;81 : 46-52.
18. Lechner HE, Frotzler A, Eser P. Relationship between self- and clinically rated spasticity in spinal cord injury. Arch Phys Med Rehabil 2006;87 : 15-9.
19. Hsieh JT, Wolfe DL, Miller WC, Curt A, SCIRE Research Team. Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord 2008;46 : 86-95.
20. Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12 : 747-768. vi.
21. Ørsnes GB, Sørensen PS, Larsen TK, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000;101 : 244-248.
22. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand 1994;89 : 274-279.
23. Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol 2009;11 : 153-161.
24. Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008;24 : 425-439.
25. Montane E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases. Neurology 2004;63 : 1357-1363.
26. Dai AI, Wasay M, Awan S. Botulinum toxin type A with oral Baclofen versus oral Tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. J Child Neurol 2008;23 : 1464-1466.
27. Medici M, Pebet M, Ciblis D. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11 : 398-405.
28. Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer F, Warter JM. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1989;10 : 709-718. (Pubitemid 18078762)
29. Lukban MB, Rosales RL, Dressler D. Effectiveness of botulinum toxin A for upper and lower limb in children with cerebral palsy: a summery of evidence. J Neural Transm 2009;116 : 319-333.
30. Lim EC-H, Seet RCS. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol Scand 2008;117 : 73-84.
31. Caty GD, Detrembleur C, Bleyenheuft C, Detombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke 2008;39 : 2803-2808.
32. Elia AE, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009;24 : 801-812.
33. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007;21 : 331-337.
34. Marciniak C, Rader L, Gagnon C. The use of botulinum toxin for spasticity after spinal cord injury. Am J Phys Med Rehabil 2008;87 : 312-317.
35. Wissel J, Ward A, Ertzgaard P et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41 : 13-25.
36. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med 2006;38 : 166-171.
37. Mohammadi B, Balouch SA, Dengler R, Kollewe K. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatment in 137 patients. Neurol Res 2010;32 : 309-313.
38. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 (Suppl. 4) 35:40.
39. Müller K, Mix E, Saberi FA, Dressler D, Benecke R. Prevalence of neutralizing antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 2009;116 : 579-585.
40. Hermann J, Geth K, Mall V et al. Clinical impact of abtibody formation to Botulinum toxin A in children. Ann Neurol 2004;55 : 732-735.
41. Bergfeldt U, Sköld C, Julin P. Short form 36 assessed health-related quality of life after focal spasticity therapy. J Rehabil Med 2009;41 : 279-281.
42. Francisco GE. The role of intrathecal baclofen therapy in the upper motor neuron syndrome. Eur Med Phys 2004;40 : 131-143.
43. Coffey RJ, Cahill D, Steers W et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78 : 226-232.
44. Dario A, Di Stefano MG, Grossi A, Casagrande F, Bono G. Long-term intrathecal Baclofen infusion in supraspinal spasticity of adulthood. Acta Neurol Scand 2002;105 : 83-7.
45. Koulousakis A, Kuchta J. Intrathecal antispastic drug application with implantable pumps: results of a 10 years follow-up study. Acta Neurochir Suppl 2007;97 : 181-184.
46. Plassat R, Perrouin Verbe PB, Menei P, Menegalli D, Mathé JF, Richard I. Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord 2004;42 : 686-693.
47. Lynn AK, Turner M, Chambers HG. Surgical management of spastcity in persons with cerebral palsy. PM R 2009;1 : 834-848.